VJOncology is committed to improving our service to you

ESMO 2019 | Health-related QoL in ipilimumab treated advanced melanoma survivors

VJOncology is committed to improving our service to you

Christian Blank

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter